SCL Science

SCL Science Net Debt per Share

The Net Debt per Share of SCL Science (246960.KQ) as of Oct 17, 2026 is 418.59 KRW. In the previous year, Net Debt per Share was 87.83 KRW — a change of 376.57% (higher).

Net Debt per Share

418.59KRW

YoY

376.57%

Last updated:

Net Debt per Share of SCL Science is 2025 418.59 KRW. Net Debt per Share of SCL Science was 2024 87.83 KRW. It decreases by 376.57% higher compared to the previous year.

The SCL Science Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2018
-226.34 KRW
Jan 1, 2019
-354.34 KRW
Jan 1, 2020
-69.14 KRW
Jan 1, 2021
232.36 KRW
Jan 1, 2022
190.74 KRW
Jan 1, 2023
-76.79 KRW
Jan 1, 2024
87.83 KRW
Jan 1, 2025
418.59 KRW
The SCL Science Net Debt per Share history
YEARNet Debt per ShareYoY
418.59KRW+376.57%
87.83KRW-214.38%
-76.79KRW-140.26%
190.74KRW-17.91%
232.36KRW-436.05%
-69.14KRW-80.49%
-354.34KRW+56.55%
-226.34KRW-4,511.79%
5.13KRW-106.46%
-79.36KRW-124.74%
320.82KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCL Science Stock analysis

What does SCL Science do? SCL Science Inc, listed on the Korean stock exchange with ticker 246960.KQ and ISIN KR7246960009, is a healthcare company headquartered in Seoul, South Korea. The company went public on February 1, 2019, as indicated by its IPO date. SCL Science Inc operates within the healthcare sector, focusing on the development and commercialization of medical products. According to the provided information, the company manufactures and sells hemostatic medical agents, which are used to control bleeding in medical procedures. The company's products include medical hemostats and sealants that utilize biomimetic technology, a technology inspired by natural biological processes. The company's website is innotherapy.com, which may provide further details about its products and services. SCL Science Inc is based in Seoul, South Korea, and its primary business activities are centered around the healthcare industry, specifically in the field of hemostatic solutions. The company's focus on biomimetic technology suggests an innovative approach to developing medical products that mimic natural biological mechanisms. The company's operations are likely aimed at providing medical professionals with effective tools for managing bleeding during surgical and other medical procedures. The company's market presence is within South Korea, though it may have international reach through its website and product distribution channels. The information provided does not include details on the company's revenue, market share, or specific competitors, nor does it mention any acquisitions or key personnel beyond the general description of its business activities. SCL Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCL Science stock

Net Debt per Share of SCL Science is 418.59 KRW in 2025.

Net Debt per Share of SCL Science changed from 87.83 KRW to 418.59 KRW, representing a 376.57% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share SCL Science since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — SCL Science

All Key Metrics — SCL Science